19 Years of Experience
Affiliated with a Castle Connolly Top Hospital
Who is Dr. Buyyounouski, Radiation Oncologist in Stanford, CA?
Dr. Mark Buyyounouski, MD is a Radiation Oncologist, who primarily practices in Stanford, CA with 2 additional practice locations. He has been practicing for over 19 years and is board certified. Dr. Buyyounouski graduated from UMDNJ - NJMS and completed his residency at Fox Chase Cancer Ctr, Radiation Oncology; St Barnabas Med Ctr, Internal Medicine. Dr. Buyyounouski is fluent in English, and is currently seeing new patients. Dr. Buyyounouski’s practice accepts Kaiser Permanente, Medicaid, Medicare, Aetna, UnitedHealthcare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Buyyounouski’s office at (215) 728-6900.
What are Areas of Expertise for Dr. Buyyounouski?
Dr. Mark Buyyounouski, MD is a highly-rated, board-certified Radiation Oncologist known for expertly diagnosing, treating, and managing a wide array of related conditions and procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Buyyounouski empowers patients to confidently navigate their health journey, specializing in Brachytherapy, Clinical Trials, Genitourinary Cancer, Prostate Cancer, Stereotactic Radiosurgery, and comprehensive wellness support. Serving the Stanford, CA community, Dr. Buyyounouski is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Buyyounouski go to medical school and complete their residency?
Residency: Fox Chase Cancer Ctr, Radiation Oncology; St Barnabas Med Ctr, Internal Medicine | Fox Chase Cancer Center
Medical School: Umdnj-New Jersey Med Sch- Newark Nj | UMDNJ - NJMS
Is Dr. Buyyounouski board certified as a Radiation Oncologist?
Yes, Dr. Mark Buyyounouski, MD is board certified by the American Board of Radiology since 2006
What languages does Dr. Buyyounouski speak?
Dr. Buyyounouski and their clinical team can communicate with patients in the following languages:
English
What conditions does a Radiation Oncologist like Dr. Buyyounouski typically treat?
As a Radiation Oncologist, Dr. Buyyounouski diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Buyyounouski. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology here.
Also known as:
- Prostate Cancer
- Prostate Cancer Treatment (PDQ®)
- Prostatic Carcinoma
- Prostate Gland Cancer
- Malignant Prostate Tumor
ICD-10 Codes:
- C61: Malignant neoplasm of prostate
Also known as:
- Secondary Cancer in Pelvic Lymph Nodes
- Secondary Cancer in Head and Neck Lymph Nodes
- Cancer
- Metastatic Cancer to Pelvic Lymph Nodes
- Pelvic Lymph Node Cancer Spread
- Lymph Node Metastasis in Pelvis
- Metastatic Cancer to Neck Lymph Nodes
- Head and Neck Lymph Node Cancer Spread
- Lymph Node Metastasis in Neck
ICD-10 Codes:
- C775: Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes
- C770: Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck
Also known as:
- Secondary Bone Cancer
- Bone Cancer
- Metastatic bone cancer
- Cancer spread to bone
- Bone metastases
ICD-10 Codes:
- C7951: Secondary malignant neoplasm of bone
What procedures does a Radiation Oncologist like Dr. Buyyounouski typically perform?
As a Radiation Oncologist, Dr. Buyyounouski performs a variety of medical procedures. This procedure information is derived from anonymized insurance claims and highlights the medical procedures most commonly performed by Dr. Buyyounouski. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology here.
Also known as:
- Prostate Radiation Guidance Marker Placement
- Prostate fiducial marker insertion
- Radiation therapy guidance markers
- Prostate dosimeter placement
- Needle placement for prostate radiation
CPT Codes:
- 55876: Placement of interstitial device(s) for radiation therapy guidance (eg, fiducial markers, dosimeter), prostate (via needle, any approach), single or multiple
Also known as:
- Prostate Seed Implants (Brachytherapy)
- Prostate Brachytherapy
- Interstitial Radioelement Application
- Prostate Radiation Seed Placement
CPT Codes:
- 55875: Transperineal placement of needles or catheters into prostate for interstitial radioelement application, with or without cystoscopy
Also known as:
- Bladder Ultrasound for Residual Urine
- Post-void residual urine measurement
- Bladder capacity ultrasound
- Non-imaging bladder scan
CPT Codes:
- 51798: Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging
Does Dr. Buyyounouski accept my insurance?
Dr. Buyyounouski accepts most major insurance plans. Important: Please call our office at (215) 728-6900 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Buyyounouski accept in Stanford, CA?
Dr. Buyyounouski in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
Blue Shield of California
Centene Corporation
Cigna Group
CVS Health (formerly Aetna)
Federal government of the United States
Medicaid
Medicare
State of California
UnitedHealth Group
View All Insurances
Where is Dr. Buyyounouski's office located?
Dr. Mark Buyyounouski's Primary Practice
300 Pasteur Dr
Stanford, CA 94305
(215) 728-6900
Recognitions
Publications
Randomized trial of hypofractioted exterl-beam radiotherapy for prostate cancer.
, 2013
Gleason Scoring at a Comprehensive Cancer Center: What's The Difference?
, 2013
Validating the Interval to Biochemical Failure
, 2012
RADIOTHERAPY DOSES OF 80 GY AND HIGHER ARE ASSOCIATED WITH LOWER MORTALITY IN MEN WITH GLEASON
, 2012
DEVELOPMENT OF RTOG CONSENSUS GUIDELINES FOR THE DEFINITION OF THE CLINICAL TARGET VOLUME FOR
, 2010
Inflammatory Bowel Disease Is Not an Absolute Contraindication to Definitive Radiation Therapy
, 2013
CT-MRI Fusion Uncertainty in Prostate Treatment Planning for Different Image Guidance Techniques
, 2013
Toxicity and Biochemical Failure Following Image
, 2013
Improved Outcomes in Men Treated With Adjuvant
, 2013
Stratifying intermediate-risk patients for radiotherapy
, 2013
Reduction of prostate intrafractiol motion from shortening the treatment time
, 2013
A Novel Method for Predicting Late Genitouriry Toxicity After Prostate Radiation Therapy
, 2013
Untitled Reply
, 2013
In reply to Cheung.
, 2013
Prospective Validation of Diagnostic Tumor Tissue Ki
, 2012
Primary Prostate Radiation Therapy: Where Are We Failing?
, 2012
Determints of Prostate Biopsy Positivity 2 Years After Radiation Therapy
, 2012
Do Testosterone Kinetics After Radiation Therapy (RT) Predict Biochemical Failure (BCF) for Low-
, 2012
Recursive Partitioning Alysis of Intermediate Risk Prostate Cancer Patients Identifies Subgroup
, 2012
A Novel Methodology to Predict Late Uriry Toxicity Following Prostate Radiation Therapy
, 2012
Aspirin and Statin Nonuse Associated With Early Biochemical Failure After Prostate Radiation
, 2012
Prostate Bed Motion During Intensity-Modulated Radiotherapy Treatment
, 2012
Radiotherapy Treatment Planning for Testicular Seminoma
, 2012
Magnetic Resonce Spectroscopy of the Prostate: A Phantom Study of Metabolite Concentrations
, 2012
Effect of Gold Marker Seeds on Magnetic Resonce Spectroscopy of the Prostate
, 2012
Testicular Cancer Clinical Practice Guidelines in Oncology
, 2012
Hypoxic Prostate/Muscle PO2 Ratio Predicts for Outcome in Patients With Localized Prostate Cancer
, 2012
Long-Term Survival After Radical Prostatectomy Versus Exterl
, 2011
INTENSITY-MODULATED RADIOTHERAPY REDUCES GASTROINTESTIL TOXICITY IN PATIENTS TREATED WITH ANDROGEN
, 2011
PREDICTORS OF ANDROGEN DEPRIVATION THERAPY EFFICACY COMBINED WITH PROSTATIC IRRADIATION
, 2011
The Impact of Gleason Scoring at a Comprehensive Cancer Center
, 2011
A Nomogram Predicting 5
, 2011
Aspirin Use Reduces the Risk of Biochemical Failure
, 2011
A Family History of Prostate Cancer is not Associated with Poorer Outcomes following Radiotherapy
, 2011
VMAT Reduces Moderate to High Integral Dose When Compared to Conventiol IMRT
, 2011
Identification of a Single Nucleotide Polymorphism Related to Late Toxicity in a R
, 2011
Potential Treatment Margin Reduction for Prostate Treatment with RapidArc and VMAT
, 2011
Five Year Results of a R
, 2011
Genetic Polymorphisms of D Repair
, 2011
Prostate Bed Motion during Intensity Modulated Radiotherapy Treatment
, 2011
Treatment-related Side Effects And Quality Of Life Among Prostate Cancer Patients Treated With
, 2011
Implantation of electromagnetic transponders following radical prostatectomy for delivery of IMRT
, 2010
STEREOTACTIC BODY RADIOTHERAPY FOR EARLY-STAGE NON-SMALL-CELL LUNG CANCER
, 2010
RADIOTHERAPY PSA dir predicts long-term mortality
, 2010
STEREOTACTIC BODY RADIOTHERAPY FOR PRIMARY MAGEMENT OF EARLY-STAGE
, 2010
Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high
, 2010
Young Age under 60 is not a Contraindication to Treatment with Definitive High Dose Exterl Beam
, 2010
Intermediate-risk Prostate Cancer Treated with High Dose Radiotherapy Alone or in Combition with
, 2010
Low Pretreatment PET SUV Predicts for Incre
, 2010
The Stamp Test Delivers the Message on Erectile Dysfunction following High Dose IMRT
, 2010
Prelimiry Results of RTOG 0233
, 2010
A Practical Strategy to Correct Prostate Rotation Reported by a 4D Localization System
, 2010
Interval to Biochemical Failure is Highly Prognostic for Distant Metastases
, 2010
Conventiol versus Hypofractioted IMRT
, 2010
The Role of Adjuvant and Salvage Post-Prostatectomy IMRT or 3DCRT: The Fox Chase Experience
, 2010
GAINS FROM REAL-TIME TRACKING OF PROSTATE MOTION DURING EXTERL BEAM RADIATION THERAPY
, 2009
Androgen Deprivation Therapy and Prostate Cancer Duration
, 2009
Optimal PET response following stereotactic body radiotherapy
, 2009
Fil report of a phase I Dose Escalation Trial of Stereotactic Body Radiotherapy
, 2009
RTOG GU RADIATION ONCOLOGY SPECIALISTS REACH CONSENSUS ON PELVIC LYMPH NODE VOLUMES FOR HIGH
, 2009
Correlation of hypoxic prostate/muscle p(O2) (P/M P-O2) ratio
, 2009
Residual Prostate Cancer After Radiotherapy
, 2009
Initial PSA (iPSA) and Radiation Dose Predict for an Undetectable PSA following 3DCRT or IMRT for
, 2009
Defining Biochemical Failure following Salvage Radiotherapy
, 2009
A Potential Outcomes Framework to Determine Whether Age
, 2009
Is MRI-based Week Three Post-implant Dosimetry Necessary following LDR Prostate Brachytherapy?
, 2009
Validating the Interval to Biochemical Failure
, 2009
Undetectable Post-treatment PSA following 3DCRT or IMRT Alone for Patients with Low or Intermediate
, 2009
Hypofractiotion for Prostate Cancer: Interim Results of a Randomized Trial
, 2009
DOES TREATMENT DURATION AFFECT OUTCOME AFTER RADIOTHERAPY FOR PROSTATE CANCER?
, 2008
Comment on dose escalation and biochemical failure in prostate cancer
, 2008
A comparison of acute
, 2008
Influence of local tumor control on distant metastases and cancer related mortality after exterl
, 2008
How can men destined for biochemical failure after androgen deprivation and radiotherapy be
, 2008
Percentage of biopsy cores positive for maligncy
, 2008
Commentary on dose escalation and biochemical failure in prostate cancer
, 2008
Predicting local persistence of intermediate
, 2008
Interval to biochemical failure highly prognostic for distant metastasis
, 2008
Low morbidity and excellent local control using image guided stereotactic body radiotherapy
, 2008
Gains from real-time prostate motion monitoring during exterl beam radiation therapy
, 2008
The optimum duration of combition androgen deprivation therapy
, 2008
Androgen deprivation therapy plus hypofractioted prostate radiotherapy
, 2008
Radiation therapy for high risk prostate cancer
, 2008
Estimating gains in biochemical outcome from various durations of
, 2008
PSA doubling time predicts for the development of distant metastases
, 2008
Prostate cancer risk assessment program: A 10-year update of cancer detection
, 2007
What dose of exterl-beam radiation is high enough for prostate cancer?
, 2007
Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer.
, 2013
Transurethral surgery
, 2013
Gleason Scoring at a Comprehensive Cancer Center: What's The Difference?
, 2013
Assessment of the American Joint Committee on Cancer Staging
, 2012
Validating the Interval to Biochemical Failure
, 2012
RADIOTHERAPY DOSES OF 80 GY AND HIGHER ARE ASSOCIATED WITH LOWER MORTALITY IN MEN WITH GLEASON
, 2012
DEVELOPMENT OF RTOG CONSENSUS GUIDELINES FOR THE DEFINITION OF THE CLINICAL TARGET VOLUME FOR
, 2010
Inflammatory Bowel Disease Is Not an Absolute Contraindication to Definitive Radiation Therapy
, 2013
CT-MRI Fusion Uncertainty in Prostate Treatment Planning for Different Image Guidance Techniques
, 2013
Toxicity and Biochemical Failure Following Image
, 2013
Improved Outcomes in Men Treated With Adjuvant or Early Salvage Postprostatectomy IMRT
, 2013
Stratifying intermediate-risk patients for radiotherapy
, 2013
Reduction of prostate intrafractional motion from shortening the treatment time
, 2013
A Novel Method for Predicting Late Genitourinary Toxicity After Prostate Radiation Therapy
, 2013
Untitled Reply
, 2013
In reply to Cheung.
, 2013
The impact of dose-escalated radiotherapy plus
, 2013
Prospective Validation of Diagnostic Tumor Tissue Ki
, 2012
Primary Prostate Radiation Therapy: Where Are We Failing?
, 2012
Determinants of Prostate Biopsy Positivity 2 Years After Radiation Therapy
, 2012
Do Testosterone Kinetics After Radiation Therapy (RT) Predict Biochemical Failure (BCF) for Low-
, 2012
Recursive Partitioning Analysis of Intermediate Risk Prostate Cancer Patients Identifies Subgroup
, 2012
A Novel Methodology to Predict Late Urinary Toxicity Following Prostate Radiation Therapy
, 2012
Aspirin and Statin Nonuse Associated With Early Biochemical Failure After Prostate Radiation
, 2012
Prostate Bed Motion During Intensity-Modulated Radiotherapy Treatment
, 2012
Stamp Test Delivers Message on Erectile Dysfunction After High-dose Intensity
, 2012
Radiotherapy Treatment Planning for Testicular Seminoma
, 2012
A survey of current clinical practice in permanent and temporary prostate brachytherapy
, 2012
Magnetic Resonance Spectroscopy of the Prostate: A Phantom Study of Metabolite Concentrations
, 2012
How Certain Can the Real-Time Plan Predict the Post Dosimetry for Prostate Seed Implant?
, 2012
Effect of Gold Marker Seeds on Magnetic Resonance Spectroscopy of the Prostate
, 2012
Biochemical and clinical experience with real
, 2012
Testicular Cancer Clinical Practice Guidelines in Oncology
, 2012
An evidence based review of proton beam therapy
, 2012
Hypoxic Prostate/Muscle PO2 Ratio Predicts for Outcome in Patients
, 2012
Young age under 60 years is not a contraindication to treatment with definitive dose escalated
, 2011
Long-Term Survival After Radical Prostatectomy Versus External
, 2011
INTENSITY-MODULATED RADIOTHERAPY REDUCES GASTROINTESTINAL TOXICITY IN PATIENTS TREATED WITH
, 2011
PREDICTORS OF ANDROGEN DEPRIVATION THERAPY EFFICACY COMBINED WITH PROSTATIC IRRADIATION
, 2011
The Impact of Gleason Scoring at a Comprehensive Cancer Center on the Ability to Predict Recurrence
, 2011
A Nomogram Predicting 5
, 2011
Aspirin Use Reduces the Risk of Biochemical Failure
, 2011
A Family History of Prostate Cancer is not Associated with Poorer Outcomes following Radiotherapy
, 2011
VMAT Reduces Moderate to High Integral Dose When Compared to Conventional IMRT
, 2011
Identification of a Single Nucleotide Polymorphism Related to Late Toxicity in a R
, 2011
Potential Treatment Margin Reduction for Prostate Treatment with RapidArc and VMAT
, 2011
Five Year Results of a R
, 2011
Genetic Polymorphisms of DNA Repair
, 2011
Prostate Bed Motion during Intensity Modulated Radiotherapy Treatment
, 2011
Treatment-related Side Effects And Quality Of Life Among Prostate Cancer Patients Treated With
, 2011
Implantation of electromagnetic transponders following radical prostatectomy for delivery of IMRT
, 2010
STEREOTACTIC BODY RADIOTHERAPY FOR EARLY-STAGE NON-SMALL-CELL LUNG CANCER
, 2010
Androgen Deprivation Therapy in High-Risk Prostate Cancer
, 2010
RADIOTHERAPY PSA nadir predicts long-term mortality
, 2010
STEREOTACTIC BODY RADIOTHERAPY FOR PRIMARY MANAGEMENT OF EARLY-STAGE
, 2010
An intraoperative real-time sleeved seed technique for permanent prostate brachytherapy
, 2010
Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high
, 2010
Young Age under 60 is not a Contraindication to Treatment with Definitive High Dose External Beam
, 2010
Intermediate-risk Prostate Cancer Treated with High Dose Radiotherapy Alone or in Combination with
, 2010
Low Pretreatment PET SUV Predicts for Incre
, 2010
The Stamp Test Delivers the Message on Erectile Dysfunction following High Dose IMRT
, 2010
Preliminary Results of RTOG 0233
, 2010
A Practical Strategy to Correct Prostate Rotation Reported by a 4D Localization System
, 2010
Interval to Biochemical Failure is Highly Prognostic for Distant Metastases
, 2010
Conventional versus Hypofractionated IMRT
, 2010
The Role of Adjuvant and Salvage Post-Prostatectomy IMRT or 3DCRT: The Fox Chase Experience
, 2010
GAINS FROM REAL-TIME TRACKING OF PROSTATE MOTION DURING EXTERNAL BEAM RADIATION THERAPY
, 2009
Androgen Deprivation Therapy and Prostate Cancer Duration
, 2009
Optimal PET response following stereotactic body radiotherapy
, 2009
Final report of a phase I Dose Escalation Trial of Stereotactic Body Radiotherapy
, 2009
Surveillance for Stage I Seminoma
, 2009
RTOG GU RADIATION ONCOLOGY SPECIALISTS REACH CONSENSUS ON PELVIC LYMPH NODE VOLUMES FOR HIGH
, 2009
Dosimetric comparison of stereotactic body radiotherapy using 4D CT
, 2009
Correlation of hypoxic prostate/muscle p(O2) (P/M P-O2) ratio
, 2009
Residual Prostate Cancer After Radiotherapy
, 2009
Race, Genetic West African Ancestry
, 2009
Initial PSA (iPSA) and Radiation Dose Predict for an Undetectable PSA following 3DCRT or IMRT for
, 2009
Defining Biochemical Failure following Salvage Radiotherapy
, 2009
A Potential Outcomes Framework to Determine Whether Age
, 2009
Is MRI-based Week Three Post-implant Dosimetry Necessary following LDR Prostate Brachytherapy?
, 2009
Validating the Interval to Biochemical Failure
, 2009
Undetectable Post-treatment PSA following 3DCRT or IMRT Alone for Patients with Low or Intermediate
, 2009
Hypofractionation for Prostate Cancer: Interim Results of a Randomized Trial
, 2009
DOES TREATMENT DURATION AFFECT OUTCOME AFTER RADIOTHERAPY FOR PROSTATE CANCER?
, 2008
Residual prostate cancer after radiotherapy: A study of radical cystoprostatectomy specimens
, 2008
Comment on dose escalation and biochemical failure in prostate cancer
, 2008
A comparison of acute
, 2008
Does transurethral resection of prostate
, 2008
Influence of local tumor control on distant metastases and cancer related mortality after external
, 2008
How can men destined for biochemical failure after androgen deprivation and radiotherapy be
, 2008
Percentage of biopsy cores positive for malignancy
, 2008
Commentary on dose escalation and biochemical failure in prostate cancer
, 2008
Predicting local persistence of intermediate
, 2008
Interval to biochemical failure highly prognostic for distant metastasis
, 2008
Low morbidity and excellent local control using image guided stereotactic body radiotherapy
, 2008
Gains from real-time prostate motion monitoring during external beam radiation therapy
, 2008
The optimum duration of combination androgen deprivation therapy
, 2008
The phoenix definition of biochemical failure predicts for overall survival
, 2008
Androgen deprivation therapy plus hypofractionated prostate radiotherapy
, 2008
Radiation therapy for high risk prostate cancer
, 2008
Estimating gains in biochemical outcome from various durations of
, 2008
PSA doubling time predicts for the development of distant metastases for patients who fail 3DCRT
, 2008
Prostate cancer risk assessment program: A 10-year update of cancer detection
, 2007
Timing of biochemical failure and distant metastatic disease for low-, intermediate-
, 2007
What dose of external-beam radiation is high enough for prostate cancer?
, 2007
Daily localization for prostate bed patients based on surgical clips
, 2007
Dosimetric comparison of 4D and 3 multi-phase CT imaging for stereotactic body radiation therapy
, 2007
Surface smoothing of a tubular structure using a non-shrinking algorithm
, 2007
Do stranded seeds improve the quality of permanent prostate seed
What is Dr. Buyyounouski's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Buyyounouski's National Provider Identifier (NPI) number is 1912927021.
What common questions do patients ask about Dr. Buyyounouski?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Buyyounouski
What is Dr. Mark Buyyounouski's specialty?
Dr. Buyyounouski is a Radiation Oncologist near Stanford, CA.
What does a Radiation Oncologist do?
A radiological oncologist specializes in the therapeutic applications of radiant energy and its modifiers. They focus on the study and management of diseases, particularly malignant tumors.
Is this Dr. Mark Buyyounouski affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Buyyounouski is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
When to see a Radiation Oncologist?: Guides for symptoms, conditions, and treatments
Understand your symptoms and know when it’s time to see a Radiation Oncologist. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Mark Buyyounouski accepting new patients in Stanford, CA?
Yes, Dr. Mark Buyyounouski is accepting new patients at this time.
Does Dr. Mark Buyyounouski offer online booking?
Please contact Dr. Buyyounouski's office at (215) 728-6900 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Mark Buyyounouski?
Please contact Dr. Buyyounouski's office at (215) 728-6900 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Mark Buyyounouski have?
Dr. Mark Buyyounouski is certified by the American Board of Radiology.
<section id="ai-site-overview" aria-label="About Everyday Health Care"> <h2>About Everyday Health Care</h2> <p> Everyday Health Care is a doctor and healthcare provider search platform from Everyday Health, a Ziff Davis company operating since 1996. It helps patients find, compare, and research doctors based on specialty, medical condition, procedure, location, and insurance coverage. </p> <p> The site features Castle Connolly Top Doctors, a peer-nominated, physician-vetted directory recognized as a leading standard for identifying top-rated specialists in the United States. Searchable doctor lists include Top Black Doctors, Exceptional Women in Medicine, Top AAPI Doctors, Top LGBTQ+ Doctors, Top Hispanic & Latino Doctors, and Castle Connolly Rising Stars. </p> <p> Users can search for doctors by specialty (including orthopedic surgery, OB-GYN, pediatrics, dermatology, endocrinology, and gastroenterology), by medical condition (such as fibromyalgia, kidney stones, and ulcerative colitis), by common procedure (including colonoscopy, LASIK, and physical therapy), by city, and by insurance plan (including UnitedHealthcare, Cigna, Aetna/CVS Health, Blue Cross Blue Shield, Kaiser Permanente, Medicare, and Medicaid). </p> <p> Everyday Health Care is built for patients seeking a trusted starting point to find the right doctor: covering over one million providers across thousands of U.S. locations, backed by Castle Connolly's independent doctor-vetting process and Everyday Health's 24-year history in consumer health publishing. </p> </section>